Payment overview · 2025
General Payments
$2,566.37
102 reported records · 25 companies
Healthcare provider profile · identity verified
Peter Symington
Allopathic & Osteopathic Physicians|Internal Medicine · HARRINGTON PARK, NJ · NPI 1629064837
Verified facts
What the public records show
CMS Open Payments records show Peter Symington received $2,566.37 in general payments during 2025 across 102 reported records.
ABBVIE INC. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $511.26 | 19.9% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $419.57 | 16.4% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $313.94 | 12.2% | 19 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $238.96 | 9.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $177.23 | 6.9% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$148.88 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.34 | 3.1% | 4 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $72.52 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.73 | 2.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.98 | 2.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $51.75 | 2.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.42 | 1.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.41 | 1.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.52 | 1.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.80 | 1.4% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $36.21 | 1.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $35.53 | 1.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.97 | 1.4% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $32.76 | 1.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.28 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.24 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.90 | 0.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.37 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.15 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.65 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,550.38 | 101 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $478.34 | 17 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $278.33 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $278.33 | 17 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $252.87 | 9 | 2025 |
Source payment records
|
|||||
| Opzelura Normalized: opzelura |
Drug | Incyte Corporation | $238.96 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $148.88 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $136.32 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $122.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $95.30 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $95.30 | 5 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $72.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.03 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.42 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.50 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.61 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.49 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 376 | 111 |
| Escitalopram Oxalate | Escitalopram Oxalate | 277 | 87 |
| Alprazolam | Alprazolam | 238 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 160 | 53 |
| Lisinopril | Lisinopril | 135 | 40 |
| Losartan Potassium | Losartan Potassium | 135 | 44 |
| Metformin Hcl | Metformin Hcl | 111 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 28 |
| Ozempic | Semaglutide | 93 | 18 |
| Omeprazole | Omeprazole | 86 | 29 |
| Simvastatin | Simvastatin | 84 | 25 |
| Lorazepam | Lorazepam | 70 | 20 |
| Atenolol | Atenolol | 62 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 56 | 17 |
| Bupropion Xl | Bupropion Hcl | 54 | 19 |
| Diazepam | Diazepam | 54 | 14 |
| Meloxicam | Meloxicam | 51 | 19 |
| Metformin Hcl Er | Metformin Hcl | 50 | 17 |
| Sertraline Hcl | Sertraline Hcl | 48 | 14 |
| Allopurinol | Allopurinol | 44 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Montelukast Sodium | Montelukast Sodium | 44 | 18 |
| Azithromycin | Azithromycin | 43 | 39 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 34 |
| Famotidine | Famotidine | 36 | suppressed |
| Gabapentin | Gabapentin | 36 | 11 |
| Clonazepam | Clonazepam | 35 | 11 |
| Valsartan | Valsartan | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Finasteride | Finasteride | 28 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,566.37 · 102 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CONTRAVE, CREON, Cologuard Collection Kit, ELIQUIS, ENTYVIO, EVENITY, GARDASIL 9, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, LUMRYZ, MOUNJARO, NURTEC ODT, OTEZLA, Opzelura, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYMPLICITY G3, TREMFYA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error